임상시험

INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections

NCT: NCT03037164 · COMPLETED

NCT IDNCT03037164

상태COMPLETED

시작일2017-05-10

완료2026-07-06

SponsorCerus Corporation (INDUSTRY)

First posted2017-01-31

Last updated2026-10-06

간략 요약

To evaluate the safety and efficacy of red blood cells (RBCs) prepared with the INTERCEPT Blood System for Red Blood Cells Pathogen Reduction Treatment (PRT) in comparison to conventional RBCs in patients who require RBC transfusion support.

공식 출처

ClinicalTrials.gov에서 보기 →

데이터는 ClinicalTrials.gov API에서 제공됩니다. 최신 상태는 공식 기록을 확인하세요.